BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32453447)

  • 1. Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms.
    Cacho-Díaz B; Salmerón-Moreno K; Alvarez-Alvarez A; Mendoza-Olivas LG; Alvarado-Miranda A; Villarreal-Garza C; Reynoso-Noverón N; Chávez-MacGregor M; Meneses-García AA
    Cancer; 2020 Aug; 126(15):3456-3463. PubMed ID: 32453447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms.
    Cacho-Díaz B; Spínola-Maroño H; Arrieta VA; Granados-García M; Wegman-Ostrosky T; Mendoza-Olivas LG; Chávez-MacGregor M
    Clin Neurol Neurosurg; 2018 Oct; 173():61-64. PubMed ID: 30086430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and outcome of HER2+ breast cancer with CNS metastases.
    Masci G; Agostinetto E; Giordano L; Bottai G; Torrisi R; Losurdo A; De Sanctis R; Navarria P; Scorsetti M; Zuradelli M; de Rose F; Bello L; Santoro A
    Future Oncol; 2020 Mar; 16(7):269-279. PubMed ID: 32043375
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
    Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Delaloge S; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Chevrot M; Pasquier D; Bachelot T
    Br J Cancer; 2019 Dec; 121(12):991-1000. PubMed ID: 31719684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
    Pasquier D; Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Petit A; Mouret-Reynier MA; Goncalves A; Dalenc F; Deluche E; Fresnel JS; Augereau P; Ferrero JM; Geffrelot J; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Mouttet-Audouard R; Bachelot T; Courtinard C
    Eur J Cancer; 2020 Jan; 125():22-30. PubMed ID: 31835235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic breast cancer subtypes and central nervous system metastases.
    Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
    Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
    Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
    Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with long-term survival in central nervous system metastases.
    Cacho-Díaz B; Spínola-Maroño H; González-Aguilar A; Arrieta O
    J Neurooncol; 2018 Oct; 140(1):159-164. PubMed ID: 30003395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
    Dawood S; Broglio K; Esteva FJ; Ibrahim NK; Kau SW; Islam R; Aldape KD; Yu TK; Hortobagyi GN; Gonzalez-Angulo AM
    Ann Oncol; 2008 Jul; 19(7):1242-1248. PubMed ID: 18334512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
    Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Jahanzeb M; Brufsky A; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Chu L; Li H; Antao V; Cobleigh M
    Clin Cancer Res; 2019 Apr; 25(8):2433-2441. PubMed ID: 30593513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of metastasis and outcome in patients with breast cancer.
    Gerratana L; Fanotto V; Bonotto M; Bolzonello S; Minisini AM; Fasola G; Puglisi F
    Clin Exp Metastasis; 2015 Feb; 32(2):125-33. PubMed ID: 25630269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
    Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
    Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
    Laakmann E; Witzel I; Fasching PA; Rezai M; Schem C; Solbach C; Tesch H; Klare P; Schneeweiss A; Salat C; Zahm DM; Blohmer JU; Ingold-Heppner B; Huober J; Hanusch C; Jackisch C; Reinisch M; Untch M; von Minckwitz G; Nekljudova V; Müller V; Loibl S
    Breast Cancer Res; 2019 May; 21(1):60. PubMed ID: 31077239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.
    Lin NU; Claus E; Sohl J; Razzak AR; Arnaout A; Winer EP
    Cancer; 2008 Nov; 113(10):2638-45. PubMed ID: 18833576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.
    Baffert S; Cottu P; Kirova YM; Mercier F; Simondi C; Bachelot T; Le Rhun E; Levy C; Gutierrez M; Madranges N; Moldovan C; Coudert B; Spaëth D; Serin D; Cotté FE; Benjamin L; Maillard C; Laulhere-Vigneau S; Durand-Zaleski I
    BMC Health Serv Res; 2013 Oct; 13():456. PubMed ID: 24176086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
    Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
    Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central Nervous System Metastases in Patients With Cervical Carcinoma.
    Cacho-Díaz B; Lorenzana-Mendoza NA; Michel-Ortega RM; Reyes-Soto G; Monroy-Sosa A; Cantú de León D; Martínez-Tláhuel JL; Herrera-Gómez A; Granados-García M
    Int J Gynecol Cancer; 2016 Nov; 26(9):1686-1689. PubMed ID: 27654265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.